Department of Geriatric Oncology, Jiangxi Cancer Hospital: Cancer Hospital Affiliated to Nanchang University, Nanchang, Jiangxi 330029, PR China; Queen Mary School, Medical Department, Nanchang University, Nanchang, Jiangxi 330006, PR China.
Department of Geriatric Oncology, Jiangxi Cancer Hospital: Cancer Hospital Affiliated to Nanchang University, Nanchang, Jiangxi 330029, PR China.
Biomed Pharmacother. 2021 Oct;142:111998. doi: 10.1016/j.biopha.2021.111998. Epub 2021 Aug 9.
Lianhua-Qingwen capsule (LQC) is a commonly used Traditional Chinese Medicine (TCM) in China and has 11 herb components. The main active ingredient can target specific molecules and perform many clinic treatment roles. LQC has been authorized by National Medical Products Administration (NMPA) of China to treat severe acute respiratory syndrome (SARS) in 2002-2003, type A influenza virus HIN1 pandemic in 2009, H7N9, H3N2 and coronavirus disease-19 (COVID19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) in 2020. It is also widely used to treat common cold with wind-heat syndrome, chronic rhinosinusitis (CRS), amygdalitis and chronic obstructive pulmonary disease. This article summarizes the advanced research progress of LQC in clinical application, mechanisms and provides new clues in the clinical application of LQC.
连花清瘟胶囊（LQC）是中国常用的一种中药，含有 11 种草药成分。其主要活性成分可以靶向特定分子，并发挥许多临床治疗作用。2002-2003 年，连花清瘟胶囊经中国国家药品监督管理局（NMPA）批准，用于治疗严重急性呼吸综合征（SARS），2009 年用于治疗甲型 H1N1 流感大流行，2020 年用于治疗由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 H7N9、H3N2 和冠状病毒病-19（COVID19）。它也被广泛用于治疗风热感冒、慢性鼻窦炎（CRS）、扁桃体炎和慢性阻塞性肺疾病。本文总结了 LQC 在临床应用、机制方面的最新研究进展，为 LQC 的临床应用提供了新线索。
